Short answer
Krystal Biotech, Inc. (KRYS) filed an 8-K current report with the SEC on October 15, 2026 reporting Item 7.01 (Regulation FD Disclosure). KB113 Gorlin Syndrome pilot data announced for basal cell carcinoma treatment.
Krystal Biotech, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- KB113 Gorlin Syndrome pilot data announced for basal cell carcinoma treatment
- Clinical results presented at PeDRA Annual Conference, October 15–17, 2026
- Poster and press release available as Exhibits 99.1 and 99.2
- Data may inform KB113’s development potential in a rare, genetically driven skin-cancer population
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Krystal Biotech, Inc. 8-K filings
Get the next KRYS 8-K as it lands
Follow KRYS for push alerts, or ask the research agent what this filing means.